

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and L MEDLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12 APR 26 PROMT: New display field available
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 14 APR 26 LIT ALERT now available on STN
NEWS 15 APR 27 NLDB: New search and display fields available
NEWS 16 May 10 PROUSDDR now available on STN
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May
and June 2004
NEWS 18 May 12 EXTEND option available in structure searching
NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20 May 17 FRFULL now available on STN
NEWS 21 May 27 STN User Update to be held June 7 and June 8 at the SLA 2004
Conference
NEWS 22 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in CAPLUS
NEWS 23 May 27 CAPLUS super roles and document types searchable in REGISTRY
NEWS 24 May 27 Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:43:34 ON 15 JUN 2004

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:43:54 ON 15 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

DICTIONARY FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10677451.str



10677451

```

chain nodes :
6 13 14 15
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
1-6 3-13 5-10 7-15 13-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-5 1-6 4-5 5-10 7-15 13-14
exact bonds :
1-2 2-3 3-4 3-13
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

```

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

```

SAMPLE SEARCH INITIATED 10:44:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 446 TO ITERATE

```

```

100.0% PROCESSED      446 ITERATIONS      50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   7653 TO 10187
PROJECTED ANSWERS:      3403 TO 5157

```

L2 50 SEA SSS SAM L1

10677451

=> s l1 sss full

FULL SEARCH INITIATED 10:44:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9450 TO ITERATE

100.0% PROCESSED 9450 ITERATIONS


SEARCH TIME: 00.00.01

4490 ANSWERS

L3 4490 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10677451a.str



chain nodes :

6 13 14

ring nodes :

1 2 3 4 5 7 8 9 10 11 12 16 17 18 19 20 21

chain bonds :

1-6 3-13 5-10 7-16 13-14

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 16-17 16-20 17-18

18-19 18-21 19-20 19-21

exact/norm bonds :

1-2 1-5 1-6 2-3 3-4 3-13 4-5 5-10 7-16 13-14 16-17 16-20 17-18 18-19

18-21 19-20 19-21

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 : 16 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
 21:Atom


L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

10677451



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 10:48:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 10:48:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS

SEARCH TIME: 00.00.01

6 ANSWERS

L6 6 SEA SSS FUL L4

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

313.36

313.57

FILE 'CAPLUS' ENTERED AT 10:48:54 ON 15 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

10677451

FILE COVERS 1907 - 15 Jun 2004 VOL 140 ISS 25
FILE LAST UPDATED: 14 Jun 2004 (20040614/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6

L7

1 L6

=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:333714 CAPLUS

DOCUMENT NUMBER: 140:357327

TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents

INVENTOR(S): Gordeev, Mikhail Fedor; Renslo, Adam; Patel, Dinesh
Vinoobhai

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-417735P P 20021009

OTHER SOURCE(S): MARPAT 140:357327

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2, R3 = H, F; R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazolyl, dihydro-5-Me-2(3H)-furanonyl, etc.; B = (CH2)n; n = 0-1; X = N, CH; Y = N, O, S; Z = NHCOR1, NHCSR1, CONHR1, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of CBZ-protected benzenamine II, e.g., prepared from benzyl 3-pyrroline-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylamino-1-chloromethylethyl ester afforded oxazolidinone III in 62% yield. In S. aureus Min. Inhibitory

10677451

Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values

ranging from 1-8 µg/mL, i.e., the MIC value of oxazolidinone III was 1 µg/mL. Compds. I are claimed useful for the treatment of skin and eye infections.


IT 681424-68-0P 681424-79-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681424-68-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-(6-oxa-3-azabicyclo[3.1.0]hex-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681424-79-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(3,6-diazabicyclo[3.1.0]hex-3-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 681424-69-1P 681424-80-6P 681424-81-7P

681424-82-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681424-69-1 CAPLUS

CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-(6-oxa-3-azabicyclo[3.1.0]hex-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681424-80-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(6-acetyl-3,6-diazabicyclo[3.1.0]hex-3-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681424-81-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(methoxyacetyl)-3,6-diazabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681424-82-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(acetyloxy)acetyl]-3,6-diazabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:43:34 ON 15 JUN 2004)

FILE 'REGISTRY' ENTERED AT 10:43:54 ON 15 JUN 2004

L1 STRUCTURE UPLOADED
 L2 50 S L1
 L3 4490 S L1 SSS FULL
 L4 STRUCTURE UPLOADED
 L5 0 S L4
 L6 6 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:48:54 ON 15 JUN 2004

L7 1 S L6

=> s l3

L8 677 L3

=> s l8 and thu

138 THU
 2161015 THUS
 2161138 THU

(THU OR THUS)

L9 99 L8 AND THU

=> s l9 and p/dt

4368212 P/DT

L10 74 L9 AND P/DT

=> s l10 and py<=2002.

22503304 PY<=2002

L11 58 L10 AND PY<=2002

=> s l11 and us/pc

1283768 US/PC

L12 42 L11 AND US/PC

=> d l12 ibib abs hitstr 1-15

L12 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:492705 CAPLUS

DOCUMENT NUMBER: 139:69253



TITLE: Preparation of phenyl oxazolidinone derivatives as potential antimicrobials

INVENTOR(S): Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 906,215.
 CODEN: USXXCO
 DOCUMENT TYPE: **Patent**
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119817	A1	20030626	US 2002-51784	20020117 <--
US 2002103186	A1	20020801	US 2001-906215	20010716 <--
US 6734307	B2	20040511		

PRIORITY APPLN. INFO.: US 2001-906215 A2 20010716
 IN 2000-DE654 A 20000717

OTHER SOURCE(S): CASREACT 139:69253; MARPAT 139:69253
 GI



AB Substituted Ph oxazolidinones, e.g. of formula I [T = heterocyclic ring, aryl; R = alkyl, halo, CN, CHO, NH₂, NO₂, etc.; X = CH, CH-S, CH-O, N; Y, Z = H, alkyl, cycloalkyl, bridging group; U, V = alkyl, F, Cl, Br, etc.; W = CH₂, CO, CH₂NH, etc.; R₁ = NHCHR₂, NR₂CSR₂; R₂ = H, alkyl, cycloalkyl, alkoxy, etc.], are prepared This invention also relates to pharmaceutical compns. containing the compds. of the present invention as antimicrobials. The compds. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. Thus, II was prepared and showed antibacterial activity against several strains.


IT 392659-38-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-38-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 392659-23-3P 392659-24-4P 392659-25-5P
 392659-26-6P 392659-27-7P 392659-28-8P
 392659-29-9P 392659-30-2P 392659-31-3P
 392659-32-4P 392659-33-5P 392659-34-6P
 392659-36-8P 392659-37-9P 392659-41-5P
 392659-42-6P 392659-43-7P 392659-44-8P
 392659-45-9P 392659-46-0P 392659-47-1P
 392659-48-2P 392659-49-3P 392659-50-6P
 392659-51-7P 392659-52-8P 392659-55-1P
 392659-56-2P 392659-57-3P 392659-58-4P
 392659-59-5P 392659-60-8P 392659-61-9P
 392659-62-0P 392659-63-1P 392659-64-2P
 392659-65-3P 392659-66-4P 392659-67-5P
 392659-68-6P 392659-69-7P 392659-70-0P
 392659-71-1P 392659-73-3P 392659-74-4P
 392659-75-5P 392659-76-6P 392659-77-7P
 392659-80-2P 392659-81-3P 392659-86-8P
 392659-87-9P 392659-88-0P 392659-90-4P
 392659-92-6P 392659-93-7P 392659-94-8P
 392659-95-9P 392660-87-6P 548762-60-3P
 548762-62-5P 548762-68-1P 548762-69-2P
 548762-70-5P 548762-71-6P 548762-72-7P
 548762-73-8P 548762-74-9P 548762-75-0P
 548762-76-1P 548762-78-3P 548762-79-4P
 548762-80-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-23-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(2-furanylcarbonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-24-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-formyl-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-25-5 CAPLUS

CN 2-Furancarboxylic acid, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-26-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[(5-bromo-2-furanyl)carbonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-27-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[[5-(chloromethyl)-2-furanyl]carbonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-28-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-29-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(oxo-2-thienylacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-30-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(3-furanylcarbonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-31-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-32-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(5-chloro-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-33-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(2-furanylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-34-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(2-thienylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-36-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(2-thienylacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-37-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-41-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(1H-pyrrol-2-ylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-42-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(3-methyl-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-43-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(3-furanylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-44-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-methyl-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-45-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-46-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-47-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-(4-thiomorpholinyl)methyl]-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-48-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-(4-morpholinylmethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 392659-49-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[[5-[(acetyloxy)methyl]-2-furanyl]methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-50-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-51-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 392659-52-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-thienyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 392659-55-1 CAPLUS

CN 3-Furancarboxamide, N-[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-56-2 CAPLUS

CN 2-Furancarboxamide, N-[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-5-bromo-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-57-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[methyl[(5-nitro-2-thienyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-58-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[methyl[(5-nitro-2-furanyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 392659-59-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[[[(5-formyl-2-furanyl)methyl]methylamino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-60-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methylamino]methyl]-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 392659-61-9 CAPLUS

CN 2-Thiopheneacetamide, N-[[[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-62-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[[methyl[(5-nitro-2-thienyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-63-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[[methyl[(5-nitro-2-furanyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 392659-64-2 CAPLUS

10677451

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[[(5-formyl-2-furanyl)methyl]methylamino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-65-3 CAPLUS

CN Benzamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-3,5-difluoro-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-66-4 CAPLUS

CN 2-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-5-bromo-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-67-5 CAPLUS

CN 2-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-68-6 CAPLUS

CN 3-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 392659-69-7 CAPLUS

10677451

CN 2-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-70-0 CAPLUS

CN 2-Thiopheneacetamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-71-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2-furanylmethyl)methylamino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-73-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[methyl[(5-nitro-2-furanyl)methyl]amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-74-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[methyl[(5-nitro-2-thienyl)methyl]amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-75-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[methyl(2-thienylmethyl)amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-76-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[methyl[(5-methyl-2-thienyl)methyl]amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-77-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[(5-bromo-2-thienyl)methyl]methylamino]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-80-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[hexahydro-4-[(5-nitro-2-thienyl)methyl]-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-81-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(3-furanylmethyl)hexahydro-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-86-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[(5-cyano-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-87-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-88-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[[5-(1,3-dioxan-2-yl)-2-furanyl]methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-90-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-(4-morpholinylcarbonyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-92-6 CAPLUS

CN 2-Thiopheneacetamide, N-[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-93-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[[[(5-formyl-2-furanyl)methyl]methylamino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-94-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-
azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392659-95-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-(fluoromethyl)-2-furanyl]methyl]-
1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-87-6 CAPLUS

CN 2-Furancarboxamide, N-[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-
azabicyclo[3.1.0]hex-6-yl]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 548762-60-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 548762-62-5 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 392659-38-0

CMF C21 H24 F N5 O6


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 548762-68-1 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[[(5S)-3-[3-fluoro-4-[4-(hydroxydiphenylacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



10677451


PAGE 2-A



RN 548762-69-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(3-furanylmethyl)methylamino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 548762-70-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(5-formyl-2-furanyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 548762-71-6 CAPLUS

10677451

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[hexahydro-4-(2-thienylacetyl)-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 548762-72-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[5-(difluoromethyl)-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 548762-73-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-[(hydroxyimino)methyl]-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 548762-74-9 CAPLUS

CN Benzeneacetic acid, 4-[[[[[5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]-2-furanyl]methylene]amino]oxy]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 548762-75-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-[(hydrazone)methyl]-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 548762-76-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[5-(hydroxymethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 548762-78-3 CAPLUS

CN 2-Furancarboxamide, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 548762-79-4 CAPLUS

10677451


CN Carbamic acid, [1-[[5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]-2-furanyl]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 548762-80-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2Z)-2-furanyl(methoxyimino)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 154590-66-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of Ph oxazolidinone derivs. as antibacterial agents)


RN 154590-66-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-04-7 CAPLUS

CN Carbamic acid, [(1 α ,5 α ,6 α)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-05-8 CAPLUS

CN Carbamic acid, [(1 α ,5 α ,6 α)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-06-9 CAPLUS

CN Carbamic acid, [[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-
azabicyclo[3.1.0]hex-6-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 392660-14-9 CAPLUS

CN Carbamic acid, [[(1 α ,5 α ,6 α)-3-[4-[(5R)-5-(azidomethyl)-2-
oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-
yl)methyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-15-0 CAPLUS

CN Carbamic acid, [[[1 α ,5 α ,6 α)-3-[4-[(5S)-5-(aminomethyl)-2-
oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-
yl)methyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-16-1 CAPLUS

CN Carbamic acid, [[(1 α ,5 α ,6 α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 392660-17-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 α ,5 α ,6 α)-6-[(methylamino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 392660-24-1 CAPLUS

CN Carbamic acid, [1-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-

fluorophenyl]-4-piperidinyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 392660-25-2 CAPLUS

CN Carbamic acid, [1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 392660-26-3 CAPLUS

CN Carbamic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidiny]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-32-1 CAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 392660-33-2 CAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 392660-34-3 CAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 392660-35-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(hexahydro-1H-1,4-diazepin-1-yl)phenyl]-

2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:356028 CAPLUS

DOCUMENT NUMBER: 138:350275

TITLE: Crystal structures of ribosome 50S subunit and its complexes with protein synthesis inhibitors and use for homology modeling and rational antibiotic design

INVENTOR(S): Steitz, Thomas A.; Moore, Peter B.; Ban, Nenad; Nissen, Poul; Hansen, Jeffrey; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; Ippolito, Joseph A.

PATENT ASSIGNEE(S): Yale University, USA; Rib-X Pharmaceuticals, Inc.

SOURCE: Eur. Pat. Appl., 215 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1308457	A1	20030507	EP 2002-255442	20020802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2002086308	A1	20020704	US 2001-922251	20010803 <--
EP 1188769	A2	20020320	EP 2001-306825	20010809 <--
EP 1188769	A3	20020710		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003153002	A1	20030814	US 2002-72634	20020208 <--
PRIORITY APPLN. INFO.:				
			US 2001-922251	A 20010803
			EP 2001-306825	A 20010809
			US 2002-348731P	P 20020114
			US 2002-352024P	P 20020125
			US 2002-72634	A 20020208
			US 2000-223977P	P 20000809
			US 2000-635708	A2 20000809

US 2001-306996P P 20010720

US 2001-309281P P 20010801

AB The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The three-dimensional structure of the large 50S ribosomal subunit from *Haloarcula marismortui* is completely refined at 2.4 Å resolution. The model includes 2876 RNA nucleotides, 2701 amino acids from 28 ribosomal proteins, 117 magnesium ions, 88 monovalent cations, and 7898 water mols. In addition, x-ray diffraction data is used to solve the structure of the large ribosome subunit complexed with each of the following antibiotics: anisomycin, blasticidin, carbomycin A, tylosin, sparsomycin, virginiamycin M, spiramycin, azithromycin, linezolid, or erythromycin. **Thus**, the invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. The methods and compns. of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism. Syntheses are described for production of hybrid antibiotics between sparsomycin and chloramphenicol (two forms of sparsochloramphenicol) and between sparsomycin and anisomycin (sparsoanisomycin).

IT 165800-03-3D, Linezolid, complexes with ribosomal 50S subunit


RL: PRP (Properties)

(crystal structures of ribosome 50S subunit and its complexes with protein synthesis inhibitors and use for homol. modeling and rational antibiotic design)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:736895 CAPLUS




DOCUMENT NUMBER: 137:247686

TITLE: Preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections

INVENTOR(S): Hester, Jackson B.
 PATENT ASSIGNEE(S): Pharmacia and Upjohn Co., USA
 SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 778,603, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: **Patent**
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137754	A1	20020926	US 2002-42916	20020109 <--
US 6642238	B2	20031104		
US 2001047004	A1	20011129	US 2001-778603	20010207 <--
PRIORITY APPLN. INFO.:			US 2000-181640P	P 20000210
			US 2001-778603	B2 20010207

OTHER SOURCE(S): MARPAT 137:247686
 GI



AB Oxazolidinone thioamides, such as I [R1 = H, NH2, alkylamino, alkenyl, alkyloxy, alkylthio, cycloalkyl, alkyl; R2, R3 = H, F, Cl, alkyl; R4 = CN, acyl, thioacyl, alkyloxyacyl, sulfonylmethylacyl, etc.] which have potent activities against gram-pos. and gram-neg. bacteria, were prepared for therapeutic use in the treatment of bacterial infections particularly of the skin and eye. Thus, PNU 255889 (II) was prepared via a multistep synthetic sequence which included N-acylation of III with MeSCH2CO2H, S-oxidation with sodium periodate, conversion of the phthalimido group to NH2 and N-thioacylation with MeCH2CS2Me. The prepared oxazolidinone thioamides were evaluated for min. inhibitory concns. of antibacterial activity against bacterial strains such as *Staphylococcus aureus*, *S. epidermidis*, *Streptococcus pneumoniae*, *Enterococcus faecalis*

Moraxella catarrhalis and H. influenzae. Pharmaceutical formulations for oral, topical, transdermal, and parenteral delivery were discussed.

IT 345224-19-3P 354578-48-6P 354578-49-7P
 354578-50-0P 354578-51-1P 354578-52-2P
 354578-53-3P 354578-54-4P 354578-55-5P
 354578-56-6P 354578-61-3P 354578-62-4P
 354578-65-7P 354578-66-8P 354578-67-9P
 354578-68-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)

RN 345224-19-3 CAPLUS

CN Carbamic acid, [[[5S]-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-48-6 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(methylsulfinyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-49-7 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(methylthio)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354578-50-0 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(methylthio)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 354578-51-1 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(methylsulfonyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354578-52-2 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(methylsulfonyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 354578-53-3 CAPLUS

CN Carbamic acid, [[(5S)-3-[4-(4-cyano-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-54-4 CAPLUS

CN 1-Piperazinecarbonitrile, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354578-55-5 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[[[(methylamino)carbonyl]oxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN	354578-56-6	CAPLUS
CN	Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[[[(methylamino)carbonyl]oxy]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



RN 354578-61-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 354578-62-4 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-65-7 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[1-oxo-3-(phenylmethoxy)propyl]-, monohydrochloride (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 354578-66-8 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(3-hydroxy-1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-67-9 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-(phenoxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-68-0 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(phenoxyacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 354578-63-5P 354578-64-6P 354819-74-2P
 354819-77-5P 354819-82-2P 354819-83-3P
 354819-85-5P 354819-86-6P 354819-87-7P
 354819-94-6P 354819-96-8P 354820-02-3P
 354820-03-4P 354820-05-6P 354820-07-8P
 354987-17-0P 354987-18-1P 354987-21-6P
 354987-23-8P 354987-24-9P 354987-25-0P
 354987-26-1P 354987-30-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of oxazolidinone thioamides with piperazine amide substituents
 for pharmaceutical use in the treatment of microbial infections)

RN 354578-63-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-[4-(1,3-dioxobutyl)-1-piperazinyl]-3-
 fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354578-64-6 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[1-oxo-3-(phenylmethoxy)propyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354819-74-2 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(methylsulfinyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354819-77-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(methylthio)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354819-82-2 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(methylsulfonyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354819-83-3 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(1-thioxoethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354819-85-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(4-cyano-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354819-86-6 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[[[(methylamino)carbonyl]oxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


 \parallel
S

RN 354819-87-7 CAPLUS

CN Carbonic acid, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


 \parallel
S

RN 354819-94-6 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 354819-96-8 CAPLUS
CN Propanethioamide, N-[[[(5S)-3-[4-[4-[(2S)-2,3-dimethoxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

||
S

RN 354820-02-3 CAPLUS
CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2S)-3-hydroxy-2-methoxy-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

||
S

RN 354820-03-4 CAPLUS
CN Propanethioamide, N-[[[(5S)-3-[4-[4-(1,2-dioxopropyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 354820-05-6 CAPLUS

CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(3-hydroxy-1-oxopropyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354820-07-8 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

 $\begin{array}{c} || \\ S \end{array}$

RN 354987-17-0 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(phenoxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354987-18-1 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 354987-21-6 CAPLUS
CN Propanethioamide, N-[[[(5S)-3-[4-[4-[(2R)-2,3-dihydroxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


||
S

RN 354987-23-8 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[3-hydroxy-2-(hydroxymethyl)-2-methyl-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 354987-24-9 CAPLUS
 CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2S)-2-hydroxy-1-oxo-3-phenylpropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 354987-25-0 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2R)-2-hydroxy-1-oxo-3-phenylpropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 354987-26-1 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-[(2R)-hydroxyphenylacetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

$$\begin{array}{c} || \\ S \end{array}$$

RN 354987-30-7 CAPLUS
 CN Propanethioamide, N-[[[(5S)-3-[4-[4-[(2S)-(acetyloxy)phenylacetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



IT 273376-76-4 273376-91-3 273376-95-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazolidinone thioamides with piperazine amide substituents
 for pharmaceutical use in the treatment of microbial infections)
 RN 273376-76-4 CAPLUS
 CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-
 piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-91-3 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-95-7 CAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 345224-18-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of oxazolidinone thioamides with piperazine amide substituents
for pharmaceutical use in the treatment of microbial infections)

RN 345224-18-2 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(phenylmethoxy)acetyl]-1-
piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

10677451

ACCESSION NUMBER: 2002:637662 CAPLUS
 DOCUMENT NUMBER: 137:185482
 TITLE: Preparation of isoquinolinylphenyloxazolidinone
 antibacterials
 INVENTOR(S): Paget, Steven D.; Weidner-Wells, Michele A.; Werblood,
 Harvey M.
 PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064574	A2	20020822	WO 2002-US3982	20020206 <--
WO 2002064574	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003176422	A1	20030918	US 2002-72534	20020206 <--
EP 1358185	A2	20031105	EP 2002-726571	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-266938P	P 20010207
			WO 2002-US3982	W 20020206
OTHER SOURCE(S):			MARPAT 137:185482	
GI				



AB Oxazolidinones I [R = OH, N3, OCH₂Ph, acyloxy, aryloxy, heteroaryloxy, O₃SR₂, (un)substituted NH₂; R₁ = substituted Ph; R₂ = Ph, tolyl, alkyl] were prepared for use as antibacterial agents, particularly against antibiotic-resistant gram pos. organisms. Thus, 1,2,3,4-tetrahydroisoquinoline was N-substituted with 3,4-F₂C₆H₃NO₂, reduced to the amine, N-benzyloxycarbonylated, and treated with (R)-glycidyl butyrate to give the alc. II [R = OH] which was mesylated, treated with K phthalimide, hydrolyzed, and N-acetylated to give II [R = NHAc]. II [R = NHAc] had min. inhibitory concns. of Staphylococcus aureus OC4172 8, S. aureus OC2878 4, and Enterococcus faecium OC3312 8 µg/mL.

IT 449175-15-9P 449175-16-0P 449175-17-1P
 449175-18-2P 449175-19-3P 449175-20-6P
 449175-21-7P 449175-22-8P 449175-23-9P

449175-24-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinylphenyloxazolidinone antibacterials)

RN 449175-15-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-16-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-17-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(3,4-dihydro-1-oxo-2,6-naphthyridin-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449175-18-2 CAPLUS

10677451

CN Acetamide, N-[[[(5S)-3-[4-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-19-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(7,8-dihydro-2-methylpyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-20-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[7,8-dihydro-2-(2-methyl-4-thiazolyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449175-21-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[7,8-dihydro-2-(4-pyridinyl)pyrido[4,3-

d]pyrimidin-6(5H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 449175-22-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(7,8-dihydro-2-pyrazinylpyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-23-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-24-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(1,4,6,7-tetrahydro-1-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 172966-53-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoquinolinylphenyloxazolidinone antibacterials)

RN 172966-53-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-oxo-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 449175-29-5P 449175-38-6P 449175-39-7P


449175-40-0P 449175-49-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of isoquinolinylphenyloxazolidinone antibacterials)

RN 449175-29-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-38-6 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449175-39-7 CAPLUS

CN 2-Oxazolidinone, 5-[[[(triphenylphosphoranylidene)amino]methyl]-3-fluorophenyl]-4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449175-40-0 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

06/15/2004



RN 449175-49-9 CAPLUS
 CN 2,6-Naphthyridin-1(2H)-one, 2-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Indus

L12 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:575074 CAPLUS
 DOCUMENT NUMBER: 137:125148
 TITLE: Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
 INVENTOR(S): Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059116	A2	20020801	WO 2001-US44731	20011129 <--
WO 2002059116	A3	20021205		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

06/15/2004

US 2003013737

A1 20030116

US 2001-996927 20011129 <--

US 6689769

B2 20040210

EP 1349853

A2 20031008

EP 2001-994117 20011129

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:



US 2000-257904P P 20001221

WO 2001-US44731 W 20011129

OTHER SOURCE(S):

MARPAT 137:125148

GI



AB Substituted quinolones I [Y1 = CH, N; Y2, Y3 = C, N; R1 = H, alkyl, cycloalkyl, haloalkyl, halophenyl, LXmQ; R2 = H, alkyl, alkoxy, halo, haloalkoxy; R1R2 = atoms required to complete an (un)substituted 5-6-membered heterocyclic or heteroarom. ring; R3 = H, F; R4 = H, Me, NH2, F; R5 = H, LXmQ; L = bond, (un)substituted NH, NH(CH2)nNH; X = (un)substituted p-C6H4, 2,5-pyridinediyl; Q = Q1, Q2, Q3; m = 0, 1; n = 0-3; R6 = OH, alkoxy, aryloxy, acylamino] were prepared. The quinolone derivs. possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases. Thus, the quinolone II was prepared from the 7-chloroquinolone and the piperazine fragments. II had min. inhibitory concs. against E. faecalis 0.25, S. aureus 0.5, S. pneumoniae 0.125, H. influenzae 8, M. catarrhalis 1, and E. coli 16 µg/mL.

IT 444335-12-0P 444335-14-2P 444335-22-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-12-0 CAPLUS

CN 3-Quinolonecarboxylic acid, 7-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 444335-14-2 CAPLUS

CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
 10-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-
 fluorophenyl]-1-piperazinyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 444335-22-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-
 oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444335-13-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-13-1 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444335-20-0P 444335-21-1P 444335-23-3P

444335-26-6P 444335-40-4P 444335-41-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-20-0 CAPLUS

CN 3-Quinolonecarboxylic acid, 1-cyclopropyl-7-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444335-21-1 CAPLUS

CN 3-Quinolinescarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444335-23-3 CAPLUS

CN 3-Quinolinescarboxylic acid, 1-cyclopropyl-7-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

06/15/2004



RN 444335-26-6 CAPLUS


CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 444335-25-5

CMF C25 H23 F2 N3 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 444335-40-4 CAPLUS

10677451

CN Acetamide, N-[[[(5S)-3-[4-(3-acetyl-6,7-difluoro-4-oxo-1(4H)-quinolinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444335-41-5 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 444335-24-4P 444335-42-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-24-4 CAPLUS

CN 3-Quinolonecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444335-42-6 CAPLUS

CN 3-Quinolonecarboxylic acid, 1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:71873 CAPLUS

DOCUMENT NUMBER: 136:123671

TITLE: Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug

INVENTOR(S): Kararli, Tugrul T.; Bandyopadhyay, Rebanta; Singh, Satish K.; Hawley, Leslie C.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005815	A1	20020124	WO 2001-US22061	20010712 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002035264	A1	20020321	US 2001-904098	20010712 <--
EP 1303271	A1	20030423	EP 2001-953462	20010712
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.:
 US 2000-218101P P 20000713
 US 2001-279285P P 20010328
 US 2001-294838P P 20010531
 US 2001-296388P P 20010606
 WO 2001-US22061 W 20010712

OTHER SOURCE(S): MARPAT 136:123671

AB A pharmaceutical composition suitable for topical administration to an eye contains a selective COX-2 inhibitor or nanoparticles of a drug of low water solubility, at a concentration effective for the treatment and/or prophylaxis of

a disorder in the eye, and 1 or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of 2-24 h. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a composition of the invention. Thus, an ophthalmic nanoparticle suspension contained valdecoxib at 2.15 mg/g, 1.2% glycerin, 0.8% EDTA disodium salt, 4.0% Gelcarin GP-379NF, 0.21% SeaSpen PF and 0.82% Povidone.


IT 165800-03-3, Linezolid 165800-04-4, Eperezolid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ophthalmic formulation of cyclooxygenase-2 inhibitor pharmaceuticals)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S) -3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 165800-04-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:935600 CAPLUS

DOCUMENT NUMBER: 136:69815

TITLE: Preparation and formulation of N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide as a gram positive bactericide

INVENTOR(S): Barbachyn, Michael R.; Zurenko, Gary E.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA


10677451

06/15/2004

SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098297	A2	20011227	WO 2001-US14854	20010614 <--
WO 2001098297	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2001011520	A	20030318	BR 2001-11520	20010614
EP 1294717	A2	20030326	EP 2001-944126	20010614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501150	T2	20040115	JP 2002-504253	20010614
US 2002156072	A1	20021024	US 2001-881189	20010615 <--
US 6605609	B2	20030812		
PRIORITY APPLN. INFO.:				
			US 2000-212474P	P 20000616
			US 2000-236595P	P 20000929
			US 2001-285587P	P 20010420
			WO 2001-US14854	W 20010614
AB	The title compound (I) was prepared Thus , benzyl 3,5-difluoro-4-(4-thiomorpholinyl)phenylcarbamate (preparation given) was cyclocondensed with (S)-N-(2-acetyloxy-3-chloropropyl)acetamide and the product oxidized to give I. Data for biol. activity of I were given.			
IT	383199-88-0P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and formulation of N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide as a gram pos. bactericide)			
RN	383199-88-0 CAPLUS			
CN	Acetamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



IT 383199-87-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and formulation of N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide as a gram pos. bactericide)

RN 383199-87-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:798038 CAPLUS

DOCUMENT NUMBER: 135:339263

TITLE: Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis

INVENTOR(S): Mesfin, Gebre-Mariam; Jensen, Richard K.


PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA

10677451

SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080841	A2	20011101	WO 2001-US10805	20010417 <--
WO 2001080841	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002010341	A1	20020124	US 2001-836804	20010417 <--
EP 1274426	A2	20030115	EP 2001-926589	20010417
EP 1274426	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531167	T2	20031021	JP 2001-577940	20010417
AT 264101	E	20040415	AT 2001-926589	20010417
PRIORITY APPLN. INFO.: US 2000-198688P P 20000420				
WO 2001-US10805 W 20010417				
OTHER SOURCE(S): MARPAT 135:339263				
AB	The use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis is provided. Thus, (S)-N-[[3-[3-fluoro-4-(4-thiomorphonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, S-oxide (I) was prepared by the reaction of (S)-N-[[3-[3-fluoro-4-(4-thiomorphonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiamine S-oxide with Et dithioacetate. I at a dose of 120 and 200 mg/kg/day orally caused an increase in bone mass and d. of trabecular bone of the sternum, femur/tibia, vertebrae, and basal cranium of rats.			
IT	216868-70-1P 216868-86-9P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (use of thioamide oxazolidinones for treatment of bone resorption and osteoporosis)			
RN	216868-70-1 CAPLUS			
CN	Thiourea, [[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 216868-86-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 216869-13-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(use of thioamide oxazolidinones for treatment of bone resorption and osteoporosis)

RN 216869-13-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 216869-14-6P 216869-39-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(use of thioamide oxazolidinones for treatment of bone resorption and osteoporosis)

RN 216869-14-6 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-39-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:545487 CAPLUS

DOCUMENT NUMBER: 135:112030

TITLE: Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration

INVENTOR(S): Percel, Phillip J.; Venkatesh, Gopi M.; Vishnupad, Krishna S.

PATENT ASSIGNEE(S): Eurand America, Inc., USA

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052848	A2	20010726	WO 2001-US1414	20010116 <--
WO 2001052848	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6451345	B1	20020917	US 2000-506051	20000217 <--
EP 1248616	A2	20021016	EP 2001-902073	20010116 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

US 2000-177233P	P	20000120
US 2000-506051	A	20000217
WO 2001-US1414	W	20010116

AB The present invention provides taste-masked microcapsules of Linezolid or the like (any member of the orally effective oxazolidinone or macrolide antibiotics), suitable for oral administration as a suspension, a fast-disintegrating, effervescent or chewable tablet, and more specifically relates to such oral dosage forms in which the bitter taste of Linezolid contained therein is masked by a combination of microencapsulation by solvent coacervation and subsequent functional membrane coating on said microcapsules. The taste-masked granules thus obtained release less than 5%, most preferably less than 3%, at a pH of 4.0 to 6.0 (pH of the saliva) but rapidly release (as a burst) at pHs of the upper intestinal tract. The taste-masked granules are optionally blended with other pharmaceutically acceptable excipients and filled into unit dose containers or compressed into fast-disintegrating/effervescent/chewable tablets. The contents of the Linezolid unit dose containers are suspended in an aqueous medium prior to oral administration to pediatric and geriatric patients, who are unwilling and/or find it difficult to swallow Linezolid tablets. In contrast, fast-disintegrating tablets on administration without water rapidly disperse into taste masked granules in the mouth. Linezolid granules containing Et cellulose were coated with Eudragit L30D for taste masking.


IT 165800-03-3, Linezolid

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinynyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:488530 CAPLUS

DOCUMENT NUMBER: 135:92625

TITLE: Preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors.

INVENTOR(S): Straub, Alexander; Lampe, Thomas; Pohlmann, Jens;
Roehrig, Susanne; Perzborn, Elisabeth; Schlemmer,
Karl-Heinz

PATENT ASSIGNEE(S) : Bayer A.-G., Germany

10677451

06/15/2004


SOURCE: Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19962924	A1	20010705	DE 1999-19962924	19991224 <--
WO 2001047919	A1	20010705	WO 2000-EP12492	20001211 <--
WO 2001047919	C2	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TR 200201636	T2	20021021	TR 2002-200201636	20001211 <--
BR 2000017050	A	20021105	BR 2000-17050	20001211 <--
EP 1261606	A1	20021204	EP 2000-993610	20001211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519141	T2	20030617	JP 2001-549389	20001211
EE 200200341	A	20031015	EE 2002-341	20001211
ZA 2002004188	A	20030527	ZA 2002-4188	20020527
BG 106825	A	20030228	BG 2002-106825	20020614
NO 2002003043	A	20020814	NO 2002-3043	20020621 <--
US 2003153610	A1	20030814	US 2002-181051	20020624 <--

PRIORITY APPLN. INFO.:

DE 1999-19962924 A 19991224
 WO 2000-EP12492 W 20001211

OTHER SOURCE(S): MARPAT 135:92625
 GI



AB Title compds. [I; R1 = (substituted) thienyl, benzothienyl; R2 = organic residue; R3-R8 = H, alkyl; with exceptions], were prepared Thus, (5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinophenyl)-1,3-oxazolidin-2-one, 5-chlorothiophene-2-carboxylic acid, hydroxybenzotriazole, EDCI, and diisopropylethylamine were stirred overnight in DMF to give 61.5% 5-chloro-N-[[[(5S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-2-thiophenecarboxamide. 5-Chloro-N-[[[(5S)-2-oxo-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-1,3-oxazolidin-5-yl]methyl]-2-thiophenecarboxamide

(preparation given) inhibited Factor Xa with IC50 = 4 nM.

IT 348626-07-3P 348626-08-4P 348626-09-5P
348626-10-8P 348626-11-9P 348626-14-2P
348626-15-3P 348626-16-4P 348626-17-5P
348626-19-7P 348626-20-0P 348626-21-1P
348626-22-2P 348626-23-3P 348626-54-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors)

RN 348626-07-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-08-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-09-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-10-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-bromo-N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-11-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-5-methyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-14-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-[4-(4-pyridinyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-15-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-16-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[[[(5-chloro-2-thienyl)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-17-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-19-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-2-oxo-3-[4-(1-piperidinyl)phenyl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-20-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348626-21-1 CAPLUS

10677451

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-22-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-2-oxo-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-23-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-2-oxo-3-[4-(1-pyrrolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348626-54-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-3-[3-fluoro-4-(4-oxido-4-

morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 168828-90-8 221201-36-1 268209-15-0

348626-45-9 348626-47-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 5-acylaminoethyloxazolidin-2-ones as Factor Xa inhibitors)

RN 168828-90-8 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221201-36-1 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268209-15-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 348626-45-9 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-[4-(4-pyridinyl)-1-piperazinyl]phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348626-47-1 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1-piperidinyl)phenyl]-, (5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 348626-50-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors)

RN 348626-50-6 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-,
(5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:482178 CAPLUS

DOCUMENT NUMBER: 135:76881

TITLE: Preparation of N-(oxoxazolidinylmethyl)thioamides and analogs as bactericides

INVENTOR(S): Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles; Poel, Toni-Jo

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: U.S., 93 pp., Cont.-in-part of U.S. 6,218,413.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6255304	B1	20010703	US 1998-200904	19981127 <--
US 6218413	B1	20010417	US 1998-80751	19980518 <--
US 6362189	B1	20020326	US 2000-712055	20001114 <--
US 6342513	B1	20020129	US 2000-713739	20001115 <--
US 2001041728	A1	20011115	US 2001-822072	20010330 <--
US 6537986	B2	20030325		
US 2002016323	A1	20020207	US 2001-822666	20010330 <--
PRIORITY APPLN. INFO.:			US 1997-48342P	P 19970530
			US 1998-80751	A2 19980518
			US 1998-200904	A3 19981127

OTHER SOURCE(S): MARPAT 135:76881

GI



II

AB RZZ1CH2NHCSR1 [I; R = e.g., N-attached-(oxo)thiaazacycloalkyl; R1 = H, (alkyl)amino, alkyl, alkoxy, etc.; Z = e.g., fluorophenylene; Z1 = e.g., 2-oxoxazolidine-3,5-diyl] were prepared **Thus**, 1,4-hexahydrothiazepine was N-arylated by 3,4-F2C6H3NO2 and the reduced and N-protected product cyclocondensed with (R)-glycidyl butyrate to give, in 4 addnl. steps, title compound II. Data for biol. activity of I were

given.


IT 216868-57-4P 216868-61-0P 216868-64-3P
216868-65-4P 216868-66-5P 216868-67-6P
216868-68-7P 216868-69-8P 216868-70-1P
216868-71-2P 216868-72-3P 216868-73-4P
216868-74-5P 216868-75-6P 216868-76-7P
216868-77-8P 216868-78-9P 216868-79-0P
216868-80-3P 216868-81-4P 216868-82-5P
216868-84-7P 216868-85-8P 216868-86-9P
216868-87-0P 216868-88-1P 216868-90-5P
216868-92-7P 216868-95-0P 216868-96-1P
216868-99-4P 221202-51-3P 221202-52-4P
221202-63-7P 268208-12-4P 268208-13-5P
268208-14-6P 268208-16-8P 268208-67-9P
268208-69-1P 273376-65-1P 273376-66-2P
273376-67-3P 273376-68-4P 273376-69-5P
273376-70-8P 273376-71-9P 273376-72-0P
273376-73-1P 273376-74-2P 273376-75-3P
273376-77-5P 273376-78-6P 273376-79-7P
273376-80-0P 273376-81-1P 273376-82-2P
273376-83-3P 273376-84-4P 273376-85-5P
273376-86-6P 273376-87-7P 273376-88-8P
273376-89-9P 273376-90-2P 273376-91-3P
273376-92-4P 343869-89-6P 347361-61-9P
347361-62-0P 347361-63-1P 347361-64-2P
347361-65-3P 347361-66-4P 347361-67-5P
347361-68-6P 347361-69-7P 347361-70-0P
347361-71-1P 347361-72-2P 347361-73-3P
347361-74-4P 347361-75-5P 347361-76-6P
347361-77-7P 347361-78-8P 347361-79-9P
347361-80-2P 347361-81-3P 347361-82-4P
347361-83-5P 347361-84-6P 347361-85-7P
347361-86-8P 347361-87-9P 347361-88-0P
347361-89-1P 347361-90-4P 347361-91-5P
347361-92-6P 347361-93-7P 347361-94-8P
347361-95-9P 347361-96-0P 347361-97-1P
347361-98-2P 347361-99-3P 347362-00-9P
347362-01-0P 347362-02-1P 347362-03-2P
347362-04-3P 347362-05-4P 347362-06-5P
347362-07-6P 347362-08-7P 347362-09-8P
347362-10-1P 347362-11-2P 347362-12-3P
347362-13-4P 347362-14-5P 347362-15-6P
347362-16-7P 347362-17-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(oxoxazolidinylmethyl)thioamides and analogs as bactericides)

RN 216868-57-4 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-61-0 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(5-methyl-1,3,4-thiadiazol-2-yl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-64-3 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-65-4 CAPLUS

CN Thiourea, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216868-66-5 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216868-67-6 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-68-7 CAPLUS

CN Thiourea, [[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-69-8 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-70-1 CAPLUS

CN Thiourea, [[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-71-2 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-72-3 CAPLUS

CN Thiourea, [[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-73-4 CAPLUS

CN Methanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-74-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-75-6 CAPLUS

CN Ethanethioamide, 2-chloro-N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-76-7 CAPLUS

CN Ethanethioamide, 2,2,2-trifluoro-N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-77-8 CAPLUS

CN Ethanethioamide, 2-fluoro-N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-78-9 CAPLUS

CN Ethanethioamide, 2,2-difluoro-N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-79-0 CAPLUS

CN Ethanethioamide, 2-cyano-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-80-3 CAPLUS

CN Ethanethioamide, 2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-81-4 CAPLUS

CN Propanoic acid, 3-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amino]-3-thioxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-82-5 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-84-7 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-85-8 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 216868-86-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-87-0 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-88-1 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-90-5 CAPLUS

CN Thiourea, [[[(5S)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-92-7 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-[[[(aminothioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(hydroxyacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216868-95-0 CAPLUS

CN Thiourea, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-96-1 CAPLUS

CN Carbamodithioic acid, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216868-99-4 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221202-51-3 CAPLUS

CN Thiourea, N'-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221202-52-4 CAPLUS

CN Thiourea, N'-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221202-63-7 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268208-12-4 CAPLUS

CN Carbamothioic acid, [[[5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268208-13-5 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268208-14-6 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268208-16-8 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268208-67-9 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 268208-69-1 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-65-1 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN . 273376-68-4 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-69-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-70-8 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273376-71-9 CAPLUS

CN Carbamothioic acid, [[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 273376-72-0 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-73-1 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-74-2 CAPLUS

CN Thiourea, N'-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-75-3 CAPLUS

CN 1-Azetidinecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-77-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273376-78-6 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 273376-79-7 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-80-0 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-81-1 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-82-2 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-83-3 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273376-84-4 CAPLUS

10677451

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-85-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-86-6 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-87-7 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273376-88-8 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(tetrahydro-1-oxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 273376-89-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-90-2 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(tetrahydro-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-91-3 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-92-4 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 343869-89-6 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 347361-61-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[4-(tetrahydro-1,4-thiazepin-4(5H)-yl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-62-0 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-63-1 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-64-2 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-65-3 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-66-4 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-67-5 CAPLUS

CN Cyclobutanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-68-6 CAPLUS

CN Cyclopentanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-69-7 CAPLUS

CN Cyclohexanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 347361-70-0 CAPLUS

CN Cyclopropaneethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 347361-71-1 CAPLUS
CN Cyclobutaneethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 347361-72-2 CAPLUS
CN Cyclopentaneethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-73-3 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-74-4 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-75-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 347361-76-6 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 347361-77-7 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-78-8 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-79-9 CAPLUS

CN Propanethioamide, 2-methyl-N-[[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 347361-80-2 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 347361-81-3 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-82-4 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-83-5 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-84-6 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-85-7 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-86-8 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-87-9 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-88-0 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-89-1 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-90-4 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-91-5 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-92-6 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-93-7 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-94-8 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-95-9 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-96-0 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-97-1 CAPLUS

CN Butanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3,3-dimethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-98-2 CAPLUS

CN Cyclobutanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347361-99-3 CAPLUS

CN Cyclopentanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-00-9 CAPLUS

CN Cyclohexanecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-01-0 CAPLUS

CN Cyclopropaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-02-1 CAPLUS

CN Cyclobutaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-03-2 CAPLUS

CN Cyclopentaneethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-04-3 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-05-4 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-06-5 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-07-6 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-08-7 CAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-09-8 CAPLUS

CN Propanethioamide, N-[[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-10-1 CAPLUS

CN Propanethioamide, 2-methyl-N-[[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-11-2 CAPLUS

CN Cyclopropanecarbothioamide, N-[[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-12-3 CAPLUS

CN Carbamothioic acid, [[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-13-4 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 347362-14-5 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10677451



RN 347362-15-6 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-16-7 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 347362-17-8 CAPLUS

CN 1-Azetidinecarbothioamide, N-[[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 154590-54-2 165800-03-3 172966-53-9

181996-80-5 195736-77-7 216869-24-8

216869-36-2 226991-66-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides)

RN 154590-54-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10677451


Absolute stereochemistry.



RN 165800-03-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 172966-53-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-oxo-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181996-80-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195736-77-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[4-(5-methyl-1,3,4-thiadiazol-2-yl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-24-8 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-36-2 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226991-66-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 168828-65-7P 168828-67-9P 168828-90-8P
198410-25-2P 216869-05-5P 216869-07-7P
216869-09-9P 216869-10-2P 216869-11-3P
216869-12-4P 216869-13-5P 216869-14-6P
216869-15-7P 216869-16-8P 216869-18-0P
216869-19-1P 216869-20-4P 216869-21-5P
216869-22-6P 216869-23-7P 216869-34-0P
216869-35-1P 216869-39-5P 216869-41-9P
216869-42-0P 216869-43-1P 216869-44-2P
216869-45-3P 216869-46-4P 216869-47-5P
216869-48-6P 216869-50-0P 273376-94-6P
273376-95-7P 273376-96-8P 273376-97-9P
273377-03-0P 273377-04-1P 273377-08-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as
bactericides)

RN 168828-65-7 CAPLUS

CN Formamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168828-67-9 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[(5S) -3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168828-90-8 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198410-25-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-05-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-07-7 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-09-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-10-2 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-11-3 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-12-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-13-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-14-6 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-15-7 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-16-8 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-18-0 CAPLUS

CN Acetamide, 2-chloro-N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-19-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-20-4 CAPLUS

CN Acetamide, 2-fluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-21-5 CAPLUS

CN Acetamide, 2,2-difluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-22-6 CAPLUS

CN Acetamide, 2-cyano-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-23-7 CAPLUS

CN Propanoic acid, 3-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-34-0 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(phenylmethoxy)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-35-1 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(hydroxyacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 216869-39-5 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-41-9 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-42-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-43-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2,6-difluoro-4-[(5S)-2-oxo-5-[[[(phenylmethoxy)carbonyl]amino]methyl]-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-44-2 CAPLUS

CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-45-3 CAPLUS

CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-46-4 CAPLUS

CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-4-(hydroxyacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-47-5 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216869-48-6 CAPLUS

CN Piperazine, 1-[2-fluoro-4-[(5R)-5-(isothiocyanatomethyl)-2-oxo-3-oxazolidinyl]phenyl]-4-(hydroxyacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216869-50-0 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 273376-94-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-95-7 CAPLUS

CN Carbamic acid, [[[5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-96-8 CAPLUS

CN Carbamic acid, [[[5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273376-97-9 CAPLUS

CN Piperazine, 1-acetyl-4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273377-03-0 CAPLUS

CN Carbamic acid, [[[5S)-3-[3-fluoro-4-(tetrahydro-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273377-04-1 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(tetrahydro-1-oxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273377-08-5 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:453092 CAPLUS

DOCUMENT NUMBER: 135:61555

TITLE: Preparation of lipopeptides as antibacterial agents

INVENTOR(S): Hill, Jason; Parr, Ian; Morytko, Michael; Siedlecki, Jim; Yu, Xiang Yang; Silverman, Jared; Keith, Dennis; Finn, John; Christensen, Dale; Lazarova, Tsvetelina; Watson, Alan D.; Zhang, Yan

PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA; et al.

SOURCE: PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044274	A1	20010621	WO 2000-US34205	20001215 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000016467	A	20020827	BR 2000-16467	20001215 <--
EP 1246838	A1	20021009	EP 2000-991867	20001215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517480	T2	20030527	JP 2001-544763	20001215
US 2004067878	A1	20040408	US 2000-737908	20001215 <--

06/15/2004

NO 2002002887 A 20020812 NO 2002-2887 20020617 <--
PRIORITY APPLN. INFO.: US 1999-170946P P 19991215
US 2000-208222P P 20000530
WO 2000-US34205 W 20001215
OTHER SOURCE(S): MARPAT 135:61555
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Lipopeptides I [R is -N(B)(X)n-A; B is X''RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl; X, X'' are C:O, C:S, C:NH, C:NRX, S:O or SO₂; n is 0 or 1; RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy; A is H, NH₂, NHRA, NRARB, heteroaryl, cycloalkyl, heterocyclyl (RA, RB are alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy) or when n is 0, then A is P(O)(OR₅₀)OR₅₁, P(O)R₅₂R₅₃, or P(O)(OR₅₀)R₅₃, where R₅₀-R₅₃ are alkyl; alternatively B and A may form a 5-7 membered heterocyclic or heteroaryl ring; R₁ is defined similarly to R (with provisos); R₂ is CH₂CR₁₇R₁₈-ring, where R₁₇ and R₁₈ are hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl, etc. or CR₁₇R₁₈ are CO, C(:S), oxime or hydrazone group] were prepared for use as antibacterials. Thus, treating daptomycin with 4-fluorobenzaldehyde and sodium triacetoxymethylborohydride in dry DMF for 24 h afforded I [R = NHCO(CH₂)₈Me, R₁ = NHCH₂C₆H₄F-4, R₂ = CH₂COC₆H₄NH₂-o], which showed MIC (S. Aureus) ≤ 1 µg/mL.


IT 165800-03-3, Linezolid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of lipopeptides as antibacterial agents)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10677451

L12 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:453090 CAPLUS

DOCUMENT NUMBER: 135:61554

TITLE: Preparation of novel lipopeptides as antibacterial agents

INVENTOR(S): Hill, Jason; Parr, Ian; Morytko, Michael; Siedlecki, Jim; Yu, Xiang Yang; Silverman, Jared; Keith, Dennis; Finn, John; Christensen, Dale; Lazarova, Tsvetelina; Watson, Alan D.; Zhang, Yan

PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044272	A2	20010621	WO 2000-US34118	20001215 <--
WO 2001044272	A3	20011129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002025924	A1	20020228	US 2000-738742	20001215 <--
EP 1240181	A2	20020918	EP 2000-986444	20001215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017026	A	20030107	BR 2000-17026	20001215
JP 2003517004	T2	20030520	JP 2001-544761	20001215
NO 2002002888	A	20020802	NO 2002-2888	20020617 <--
PRIORITY APPLN. INFO.:			US 1999-170943P	P 19991215
			WO 2000-US34118	W 20001215
OTHER SOURCE(S):			MARPAT 135:61554	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Lipopeptides I [R is -N(B)(X)n-A; B is X'RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl; X, X' are C:O, C:S, C:NH, C:NRX, S:O or SO₂; n is 0 or 1; RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy; A is H, NH₂, NHRA, NRARB, heteroaryl, cycloalkyl, heterocyclyl (RA, RB are alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy) or when n is 0, then A is P(O)(OR₅₀)OR₅₁, P(O)R₅₂R₅₃, or P(O)(OR₅₀)R₅₃, where R₅₀-R₅₃ are alkyl (with provisos); R₁ is defined similarly to R; R₂ is CH₂CR₁₇R₁₈-ring, where R₁₇ and R₁₈ are hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl, etc. or CR₁₇R₁₈ are CO, C(:S), oxime or hydrazone

06/15/2004

group] were prepared for use as antibacterials. Thus, daptomycin was Boc-protected, deacylated using deacylase enzyme, and reacted with octyl isocyanate to give I [R = NHCONH(CH₂)₇Me, R₁ = NH₂, R₂ = CH₂COC₆H₄NH₂-o], which showed MIC (S. Aureus) > 1 ≤ 10 µg/mL mg/kg.


IT 165800-03-3, Linezolid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of novel lipopeptides as antibacterial agents)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:453089 CAPLUS

DOCUMENT NUMBER: 135:61553

TITLE: Preparation of novel lipopeptides as antibacterial agents

INVENTOR(S): Hill, Jason; Parr, Ian; Morytko, Michael; Siedlecki, Jim; Yu, Xiang Yang; Silverman, Jared; Keith, Dennis; Finn, John; Christensen, Dale; Lazarova, Tsvetelina; Watson, Alan D.; Zhang, Yan

PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044271	A2	20010621	WO 2000-US34051	20001215 <--
WO 2001044271	A3	20020307		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

10677451

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2002058785 A1 20020516 US 2000-739535 20001215 <--
 EP 1240182 A2 20020918 EP 2000-991409 20001215 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2000017028 A 20030107 BR 2000-17028 20001215
 JP 2003517003 T2 20030520 JP 2001-544760 20001215
 NO 2002002886 A 20020802 NO 2002-2886 20020617 <--
 PRIORITY APPLN. INFO.: US 1999-170945P P 19991215
 WO 2000-US34051 W 20001215
 OTHER SOURCE(S): MARPAT 135:61553
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Lipopeptides I [R and R1 are -N(B)(X)n-A; B is X'RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl; X, X' are C:O, C:S, C:NH, C:NRX, S:O or SO2; n is 0 or 1; RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy; A is H, NH2, NHRA, NRARB, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl (RA, RB are alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy) or when n is 0, then A is P(O)(OR50)OR51, P(O)R52R53, or P(O)(OR50)R53, where R50-R53 are alkyl; alternatively, B and A together form a 5-7 membered heterocyclic or heteroaryl ring; R2 is CH2CR17R18-ring, where R17 and R18 are hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl, etc. or CR17R18 are CO, C(:S), oxime or hydrazone group] were prepared for use as antibacterials. Thus, sulfamic acid (89.9 mg) and sodium nitrite (51.1 mg) were added to a solution of daptomycin (1 g) in 0.1 M HCl (31 mL) at 0°. Aqueous potassium O-ethylxanthic acid (497 mg) was added and the mixture was heated at 60° for 1 h to afford I [R = NHCO(CH2)8Me, R1 = NH2, R2 = CH2CO-o-C6H4SC(S)OEt], which showed MIC (S. Aureus and E. faecalis) and ED50 > 1 ≤ 10 µg/mL or mg/kg, resp.

IT 165800-03-3, Linezolid
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of novel lipopeptides as antibacterial agents)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:453039 CAPLUS

DOCUMENT NUMBER: 135:46171

TITLE: Preparation of N-[[[(benzoyloxyacetyl)piperazinolphenyl]loxazolidinylmethyl]alkanthioamides and analogs as bactericides

INVENTOR(S): Hester, Jackson B., Jr.

PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044212	A1	20010621	WO 2000-US32432	20001206 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001018058	A5	20010625	AU 2001-18058	20001206 <--
US 6281210	B1	20010828	US 2000-732088	20001206 <--
BR 2000015177	A	20020618	BR 2000-15177	20001206 <--
EP 1242395	A1	20020925	EP 2000-980849	20001206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003516977	T2	20030520	JP 2001-544702	20001206
ZA 2002002953	A	20030715	ZA 2002-2953	20020415
NO 2002002811	A	20020613	NO 2002-2811	20020613 <--
PRIORITY APPLN. INFO.: US 1999-170675P P 19991214				
WO 2000-US32432 W 20001206				

OTHER SOURCE(S): MARPAT 135:46171

10677451

AB R4Z4CO2CH2COZ1Z2Z3CH2R [I; R = NHC(:X)R1 or ZR9; R1 = H, (alkyl)amino, alkyl, alkoxy, etc.; R4 = NR5COCHR6NR7R8 or CHR5NR7R8; R5 = H or Me; R6 = H or (un)substituted alkyl; R7,R8 = H or alkyl; NR7R8 = heterocyclyl; R9 = heterocyclyl; Z = O, S, NH; Z1 = piperazine-1,4-diyl throughout; Z2 = 2,6-(un)substituted-1,4-phenylene; Z3 = e.g., 2-oxo-3,5-oxazolidinediyl; Z4 = 1,3- or 1,4-phenylene] were prepared for use against gram neg. bacteria. Thus, (S)-R10Z1Z2Z3CH2NHR11 (II; Z2 = 2-fluoro-1,4-phenylene, Z3 = 2-oxo-3,5-oxazolidinediyl) (III; R10 = H, R11 = Boc) was amidated by PhCH2OCH2COCl and the debenzylated product esterified by 4-(ClH2C)C6H4COCl to give, after amination and deprotection, III [R10 = 4-(Me2NH2C)C6H4CO2CH2CO] (IV; R11 = H). The latter was amidated by EtCS2Me to give IV (R11 = CSEt). Data for biol. activity of I were given.

IT 345224-04-6P 345224-05-7P 345224-06-8P
345224-07-9P 345224-08-0P 345224-09-1P
345224-10-4P 345224-12-6P 345224-13-7P
345224-14-8P 345224-15-9P 345224-16-0P
345224-17-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[[[(benzyloxyacetyl)piperazino]phenyl]oxazolidinylmethyl]alkanthioamides and analogs as bactericides)

RN 345224-04-6 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


 \parallel
S

RN 345224-05-7 CAPLUS

CN Benzoic acid, 3-[(dimethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


 \parallel
S

RN 345224-06-8 CAPLUS

CN Benzoic acid, 3-(4-morpholinylmethyl)-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


$$\begin{array}{c} || \\ S \end{array}$$

RN 345224-07-9 CAPLUS

CN Benzoic acid, 3-[(4-methyl-1-piperazinyl)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


||
S

RN 345224-08-0 CAPLUS

CN Benzoic acid, 3-[(diethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


$$\begin{array}{c} || \\ S \end{array}$$

RN 345224-09-1 CAPLUS

CN Benzoic acid, 4-[(diethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


$$\begin{array}{c} || \\ S \end{array}$$

RN 345224-10-4 CAPLUS

CN Benzoic acid, 4-(4-morpholinylmethyl)-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-
 [[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-
 oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

 $\begin{array}{c} || \\ S \end{array}$

RN 345224-12-6 CAPLUS
CN Benzoic acid, 4-[(4-methyl-1-piperazinyl)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


$$\begin{array}{c} || \\ \text{S} \end{array}$$

RN 345224-13-7 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-
 [[[(cyclopropylthioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-
 fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 345224-14-8 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[[aminothioxomethyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 345224-15-9 CAPLUS

CN Benzoic acid, 4-[(aminoacetyl)amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


 $\begin{array}{c} || \\ S \end{array}$

RN 345224-16-0 CAPLUS

CN Benzoic acid, 4-[(aminoacetyl)amino]-, 2-[4-[4-[(5S)-5-
[[[(cyclopropylthioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-
fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


S

RN 345224-17-1 CAPLUS

CN Benzoic acid, 4-[[[(2S)-2-amino-1-oxopropyl]amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

$$\begin{array}{c} || \\ \text{S} \end{array}$$

IT 273376-95-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-[[[3-fluoro-4-(1-piperazinyl)phenyl]oxazolidinylmethyl]alkanthioamides and analogs as bactericides)

RN 273376-95-7 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 345224-18-2P 345224-19-3P 345224-20-6P
 345224-21-7P 345224-22-8P 345224-23-9P
 345224-24-0P 345224-25-1P 345224-26-2P
 345224-27-3P 345224-28-4P 345224-29-5P
 345224-30-8P 345224-31-9P 345224-32-0P
 345224-33-1P 345224-34-2P 345224-35-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-[[[(benzyloxycarbonyl)amino]methyl]thio]-2-oxo-1,3-dioxolane-5-carboxamide and analogs as bactericides)

RN 345224-18-2 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 345224-19-3 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 345224-20-6 CAPLUS

CN Benzoic acid, 4-(chloromethyl)-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 345224-21-7 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonylamino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 345224-22-8 CAPLUS
 CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 345224-23-9 CAPLUS

CN Benzoic acid, 3-(chloromethyl)-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 345224-24-0 CAPLUS

CN Benzoic acid, 3-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 345224-25-1 CAPLUS

CN Benzoic acid, 3-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 345224-26-2 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 345224-27-3 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5R)-5-(isothiocyanatomethyl)-2-oxo-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 345224-28-4 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(4-nitrobenzoyl)oxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 345224-29-5 CAPLUS
 CN Carbamic acid, [[(5S)-3-[4-[4-[[[(4-aminobenzoyl)oxylacetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 345224-30-8 CAPLUS
 CN Benzoic acid, 4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-B



PAGE 2-A

● HCl

PAGE 2-B




RN 345224-32-0 CAPLUS
 CN Benzoic acid, 4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]-,
 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX
 NAME)


10677451

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 345224-33-1 CAPLUS

CN Benzoic acid, 4-[[[(2S)-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 345224-34-2 CAPLUS

CN Benzoic acid, 4-[[[(2S)-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 345224-35-3 CAPLUS
CN Benzoic acid, 4-[[[(2S)-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

||
S

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
86.00	399.57

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-11.09	-11.09

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:52:42 ON 15 JUN 2004

10677451